Evo ICL Launches In The U.S.

Dr. Jonathan Woolfson

FOR IMMEDIATE RELEASE

Evo ICL Launches In The U.S.; An Evolutionary Vision Correction Procedure To Treat Nearsightedness Is Now Available In Metro Atlanta

Ophthalmologists at Woolfson Eye Institute-Atlanta Among First to Offer EVO ICL to Provide Visual Freedom from Glasses and Contact Lenses

Atlanta, GA; May 25, 2022 — EVO ICL (“EVO”) is the newest version of the clinically proven implantable lens that corrects common vision problems such as nearsightedness for patients with (or without) astigmatism. While over 1 million EVO lenses have been implanted around the globe, EVO ICL is now FDA approved in the United States and can offer a new solution for those who seek clear vision and want to be free from the inconveniences of contact lenses or glasses. ¹ EVO is now available at Woolfson Eye Institute, making it one of the first ophthalmologist practices in the Southeast to offer this breakthrough vision correcting procedure.

“As a LASIK surgeon, I see patients who struggle with their eyesight every day and I am thrilled that there is a new lens-based solution available to help liberate patients from glasses and contacts, especially for those who can’t have LASIK,” said practice founder, Jonathan Woolfson, MD. “I’m excited to offer another alternative to our patients that delivers clear vision, excellent night vision and even UV protection, with little to no dry eye side effects, and without the need to remove any corneal tissue. The EVO procedure is a 20-30 minute procedure with a quick recovery and little downtime.  The procedure is performed at our practice by some really great cataract surgeons, as the procedures are quite similar.”  The Woolfson Eye surgeons offering EVO are Byron Cook, MD; James Hays, MD; Eric Jennings, MD; and Leo Zlotcavitch, MD.

The EVO ICL lens is slightly smaller than a typical contact lens and is implanted in the eye between the iris (colored part of the eye) and the natural lens for improvement in vision. The EVO lens is different from other vision correction options, like LASIK, performed by ophthalmologists as it is additive; meaning, it is implanted inside the eye rather than requiring removal of corneal tissue. The EVO ICL lens is new to the US market, but over 1,000,000 EVO ICL lenses have been implanted in Europe, Asia and other places around the world.

Patients report that the EVO procedure is life changing—no more struggling with wearing contact lenses and glasses.  After a successful surgery, most are quick to recommend this procedure for anyone who wants to get rid of their glasses or contacts, and describe it as a quick and easily tolerated procedure that provides vision improvement almost immediately.

Myopia (or nearsightedness) is the most common ocular disorder worldwide and its prevalence is increasing. An estimated 30% of the world’s population, or 2.6 billion people, have myopia and this number is projected to rise to 50% of the global population by the year 2050.²  Offering a new solution for myopia, the EVO ICL lens is made from Collamer®, a collagen co-polymer proprietary to STAAR Surgical, that provides UV protection. The EVO ICL lens can permanently correct vision and, if desired, is removable by the surgeon, providing patients with flexibility for the future while helping to eliminate dependency on glasses and contact lenses now.  For more information visit https://us.discovericl.com/

Important Safety Information for EVO ICL

The EVO ICL lens is intended to correct/reduce nearsightedness between -3.0 up to -20.0 D and treat astigmatism from 1.0 D to 4.0 D. If you have nearsightedness within these ranges, EVO ICL surgery may improve your distance vision without eyeglasses or contact lenses. Because the EVO ICL corrects for distance vision, it does not eliminate the need for reading glasses, you may require them at some point, even if you have never worn them before. Since implantation of the EVO ICL is a surgical procedure, before considering EVO ICL surgery you should have a complete eye examination and talk with your eye care professional about EVO ICL surgery, especially the potential benefits, risks, and complications. You should discuss the time needed for healing after surgery. Complications, although rare, may include need for additional surgical procedures, inflammation, loss of cells from the back surface of the cornea, increase in eye pressure, and cataracts. You should NOT have EVO ICL surgery if your doctor determines that 1) the shape of your eye is not appropriate, 2) you do not meet the minimum endothelial cell density for your age at the time of implantation, 3) you have moderate to severe glaucoma, 4) your vision is not stable; or 5) if you are pregnant or nursing. For additional information with potential benefits, risks and complications please visit DiscoverICL.com.

About Woolfson Eye Institute

Woolfson Eye Institute, headquartered in Atlanta, GA, is the Southeast’s leading ophthalmology treatment provider for LASIK, oculoplastics, cataract surgery, retina, glaucoma and other eye diseases and treatments to significantly improve patients’ vision and quality of life.  WEI has state-of-the-art surgery centers in Georgia, North Carolina, and Tennessee along with a fully accredited Ambulatory Surgery Center in Atlanta (Permit #: 060-414).

Contact:

Delene Graham
1-866-LASER22
dgraham@woolfsoneye.com